Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving AstraZeneca (AZN)

NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- AstraZeneca plc (NYSE: AZN) shares dropped approximately 8% premarket on July 9, 2026, after the Company announced that the Phase III CARDIO-TTransform trial of Wainua failed to meet its primary endpoint in ATTR cardiomyopathy. If you held AZN and lost money, you are encouraged to check your eligibility to recover losses now . You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.